Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Slide 57
Solid volume growth in the Chinese insulin market
Chinese insulin market by segment
Device penetration
tMU
CAGR volume¹: 10.7%
55
CAGR value¹: 14.7%
50
45
40
35
30
25
20
15
10
5
0
Nov
2012
Chinese insulin volume market shares
Novo Nordisk
Eli Lilly
Gan & Lee
Tonghua Dongbao
Other
-
Modern insulin penetration
Penetration
Sanofi
100%
70%
60%
- 80%
Fast-acting
50%
60%
40%
30%
Premix
40%
20%
20%
10%
Long-acting
0%
0%
Nov
2017
Nov
2012
1 CAGR for 5-year period
Note: IQVIA covers around 50% of the total Chinese market (hospital data)
Source: IQVIA (formerly IMS) monthly MAT Nov, 2017 volume and value (DKK) figures
changing
diabetes®
-53%
12%
12%
10%
7%
6%
Nov
2017
Note: Only selected competitors shown
Source: IQVIA (formerly IMS) monthly MAT Nov, 2017 volume figures, numbers do not add
up to 100% due to smaller insulin manufacturers not included
novo nordiskView entire presentation